REGENTIS BIOMATERIALS LTD. (RGNT) — SEC Form D Filing

REGENTIS BIOMATERIALS LTD. (RGNT) filed an SEC Form D on June 25, 2026, reporting $6.50M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
June 25, 2026
Amount reported
$6.50M
Industry
Medical Devices
Website
https://www.regentis.co.il/

What the company does

Securities: Equity. Exemption: Rule 506(c). Incorporated: ISRAEL

Problem

Patients suffer from painful injuries to articular knee cartilage, and there is an unmet need for effective treatments for these cartilage injuries.

Solution

Regentis Biomaterials is developing GelrinC, a cell-free, off-the-shelf degradable hydrogel implant designed to treat painful articular knee cartilage injuries and regenerate damaged tissue.

Verdict

Investors backed this company for its defined focus on treating articular knee cartilage injuries, not for broad regenerative medicine claims. The implicit bet was on GelrinC's ability to navigate clinical trials and regulatory hurdles more efficiently than cell-based therapies, leveraging an off-the-shelf characteristic to streamline surgical procedures. Upside was limited by the specialized application, suggesting a niche market penetration rather than a platform technology that could address multiple tissue types. This cleared because of a clearly scoped clinical pathway, not because of unproven future therapeutic modalities.

Source: SEC EDGAR Form D filing